Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

Disease-modifying drugs (DMDs) may alter the immune status and thus increase the susceptibility to coronavirus disease 2019 (COVID-19) in patients with MS or neuromyelitis optica spectrum disorders (NMOSD). However, evidence supporting this notion is currently lacking. In this study, we conducted a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neurology : neuroimmunology & neuroinflammation 2020-09, Vol.7 (5), p.e787-e787
Hauptverfasser:	Fan, Moli, Qiu, Wei, Bu, Bitao, Xu, Yan, Yang, Huan, Huang, Dehui, Lau, Alexander Y., Guo, Jun, Zhang, Mei-Ni, Zhang, Xinghu, Yang, Chun-Sheng, Chen, Jingshan, Zheng, Pei, Liu, Qiang, Zhang, Chao, Shi, Fu-Dong
Format:	Artikel
Sprache:	eng
Schlagworte:	China - epidemiology Coronavirus Infections - epidemiology COVID-19 Disease Susceptibility Humans Immunologic Factors - therapeutic use Immunosuppressive Agents - therapeutic use Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Neuromyelitis Optica - drug therapy Neuromyelitis Optica - epidemiology Pandemics Pneumonia, Viral - epidemiology Risk
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!